MATRx plus

by Zephyr Sleep Technologies  · Based in Canada → — AI-powered at-home sleep testing for confident oral appliance therapy.
Dentistry Pulmonology Sleep Medicine

Not available (company is out of business)
Regulatory Status Disclosed

Overview

MATRx plus by Zephyr Sleep Technologies was an FDA-cleared, at-home medical device designed to identify patients with obstructive sleep apnea (OSA) who were suitable for oral appliance therapy. The device functioned as both a standard home sleep test (HST) and an oral appliance trial. Utilizing proprietary algorithms, artificial intelligence, and machine learning, it analyzed patient data to recommend an optimal therapeutic mandibular position, aiming to reduce treatment failure rates. The system featured a tablet-based design with instructional videos for patient ease-of-use and offered real-time cloud connectivity to facilitate collaboration among dentists, sleep physicians, and other healthcare professionals. Zephyr Sleep Technologies ceased operations in June 2021, and MATRx plus is no longer available for sale.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • At-home sleep testing (HST)
  • Oral appliance trial/theranostic test
  • Identifies suitability for oral appliance therapy
  • Recommends therapeutic mandibular position for oral appliances
  • Tablet-based design with instructional videos for patients
  • Real-time cloud connectivity for healthcare professional collaboration
  • Proprietary algorithms, artificial intelligence, and machine learning
  • Records respiratory airflow, snoring, blood oxygen saturation, pulse, respiratory effort, and body position
  • Eliminated nasal cannula requirement with 2020 update
  • Aimed to reduce oral appliance treatment failure rates

Use Cases

  • Diagnosis of obstructive sleep apnea (OSA)
  • Patient selection for oral appliance therapy
  • Optimizing oral appliance treatment position
  • Remote patient monitoring for sleep-disordered breathing
  • Facilitating collaboration between dentists and sleep physicians
  • Conducting home-based sleep studies

What Physicians Need to Know

Triage Prioritization Speed
MATRx plus utilizes proprietary algorithms, artificial intelligence, and machine learning to predict if a patient with mild to moderate obstructive sleep apnea (OSA) is suitable for oral appliance therapy and to recommend a target mandibular position. This streamlines the selection process for oral appliance treatment, reducing guesswork and potentially accelerating the initiation of effective therapy. [1, 2, 3, 5, 6, 9, 10, 11, 12, 13]
Mobile Notification System
The MATRx plus features a tablet-based design with real-time, cloud connectivity, allowing for instant collaboration among health professionals. This system facilitates the simultaneous delivery of patient study data to the dentist's office, sleep physician's office, and Zephyr's servers, implying a system for timely access and potentially notifications regarding study results. [1, 6, 8]
Physician Tip

Physicians should be aware that MATRx plus was a home-based medical device designed to identify patients suitable for oral appliance therapy in treating obstructive sleep apnea (OSA) and to recommend a target mandibular position using AI and machine learning. It was FDA-cleared for this specific purpose. However, Zephyr Sleep Technologies, the company that developed MATRx plus, ceased operations in June 2021, and the MATRx plus device is no longer available for sale. [8] Therefore, while its technological approach was innovative for OSA management, it is not currently an active option for clinical use.

MATRx plus was designed with real-time, cloud connectivity to facilitate instant collaboration among healthcare professionals, including dentists and sleep physicians. [1, 6] It utilized a tablet-based system to guide patients through self-administered tests at home and transmit data for analysis. The technology used proprietary algorithms, AI, and machine learning to analyze sleep study data and generate reports for healthcare providers. [1, 6, 8, 9, 10]

Details

Category Neurology AI, Wearables & Remote Monitoring (RPM)
Pricing Not available (company is out of business) — N/A
DeploymentHybrid (physical device for home use, cloud-based data processing)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Yes AI-estimated

The MATRx plus received De Novo Class II medical device clearance from the FDA on September 4, 2018, for identifying OSA patients suitable for oral appliance therapy and performing home sleep tests and oral appliance trials. An update in November 2020 received 510(k) clearance, simplifying the test by eliminating the nasal cannula requirement.

Integrations
EHR Not specified
Specialties Dentistry, Pulmonology, Sleep Medicine

What the Web Says

The MATRx plus is generally well-received by physicians for its ability to objectively identify patients who will benefit from oral appliance therapy for sleep apnea, thereby improving treatment outcomes and patient satisfaction. Its in-home diagnostic capabilities are a significant advantage, though some users note a learning curve with the technology and potential for patient discomfort during the study.

Overall: Positive

Strengths

  • Objective identification of oral appliance responders
  • Improved treatment outcomes and patient satisfaction
  • In-home diagnostic testing for patient convenience
  • Reduces unnecessary oral appliance prescriptions
  • Provides data-driven insights for treatment planning
  • Potential for increased practice efficiency

Limitations

  • Learning curve for physicians and staff
  • Potential for patient discomfort during the study
  • Cost of the device and associated consumables
  • Requires proper patient education for accurate results
  • Data interpretation can be complex for new users
  • Limited information on long-term device durability

Based on reviews from: ResMed (manufacturer information), Dental Sleep Practice Magazine, Sleep Review Magazine, Various physician forums and discussions, Clinical studies and research papers

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate MATRx plus

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Dentsply Sirona Press Release
Dentsply Sirona and Zephyr Sleep Technologies Present Simple Sleep Solution
Dentsply Sirona and Zephyr Sleep Technologies announced the FDA clearance of MATRx plus, an at-home Class II medical device for identifying obstructive sleep apnea patients suitable for oral appliance therapy. The 'Simple Sleep Solution' combines MATRx plus with Dentsply Sirona 3D Imaging, SICAT Air, and OPTISLEEP for an end-to-end solution.
2018-09
Dentalcompare
New Dental Product: MATRx plus Sleep Diagnostic System from Zephyr Sleep Technologies
Zephyr Sleep Technologies received FDA approval to sell its MATRx plus multi-functional sleep diagnostic system in the US, allowing patients to identify obstructive sleep apnea and be fitted for an oral sleep appliance at home. The tablet-based system uses AI and machine learning to determine if an oral appliance will work and the most effective treatment position.
2018-09
CTV News
Technology developed in Calgary uses motorized mouthpieces to assess needs of sleep apnea patients - CTV News
Calgary-based Zephyr Sleep Technologies developed the MATRx Plus, a wearable technology that monitors breathing and blood oxygen levels while a motorized mouthpiece adjusts jaw position to determine if a dental device will effectively treat sleep apnea. This at-home testing device aims to reduce treatment failure rates and provide a precise therapeutic position for oral appliances.
2018-01
DentistryIQ
MATRx plus u2014 makes treatment and screening better for sleep issues for dentists and patients
The MATRx plus device has been validated in two clinical trials, demonstrating a positive predictive value of 97% and target protrusion accuracy of 86% for oral appliance therapy in obstructive sleep apnea. This technology, part of 'The Simple Sleep Solution,' aims to improve treatment and screening for sleep issues by providing dentists with advance knowledge of treatment effectiveness and target protrusion.
2019-09
Sleep Review
FDA Reclassifies Auto Titration Device for Oral Appliances to Enhance Patient Access to Beneficial Innovation | Sleep Review
The FDA reclassified auto titration devices for oral appliances, including Zephyr Sleep Technologies' MATRx plus, from Class III to Class II, effective February 20, 2019. This reclassification aims to reduce regulatory burdens and enhance patient access to innovative devices for the reduction of snoring and mild to moderate obstructive sleep apnea.
2019-02
Journal of Clinical Sleep Medicine (via PMC)
In-home mandibular repositioning during sleep using MATRx plus predicts outcome and efficacious positioning for oral appliance treatment of obstructive sleep apnea - PMC
A study published in the Journal of Clinical Sleep Medicine in March 2022 found that the MATRx plus system, using artificial intelligence, accurately predicts the outcome and efficacious mandibular position for oral appliance therapy in obstructive sleep apnea. The AI method showed significantly higher predictive accuracy compared to a heuristic method.
2022-03
accessdata.fda.gov
August 24, 2020 Zephyr Sleep Technologies Sabina Bruehlmann Director, Technology 102, 701 64 Ave SE Calgary, Alberta T2H-2C3 Can - accessdata.fda.gov
An FDA document from August 2020 details the indications for use of the MATRx plus, stating it is for lay person use at home and in hospitals under professional direction to record sleep data and aid in diagnosing sleep-disordered breathing. It can also identify patients suitable for oral appliance therapy and recommend a target mandibular position.
2020-08
Dental Tribune
Dentsply Sirona and Zephyr Sleep Technologies announce partnership - Dental Tribune
In September 2017, Dentsply Sirona and Zephyr Sleep Technologies announced a partnership to offer a more efficient approach to treating obstructive sleep apnea (OSA). This collaboration integrates Zephyr's MATRx Plus with Dentsply Sirona's 3D imaging, SICAT Air software, and the SICAT OPTISLEEP appliance.
2017-09

Videos

Product demos, reviews, and walkthroughs for MATRx plus.

View all on YouTube

Frequently Asked Questions

MATRx plus was an FDA-cleared, at-home Class II medical device designed to identify patients with mild to moderate obstructive sleep apnea (OSA) who were suitable for oral appliance therapy (OAT). It utilized proprietary algorithms, artificial intelligence, and machine learning to perform a home sleep test and recommend a target mandibular position for an oral appliance.
MATRx plus received De Novo Class II medical device clearance from the FDA and was intended for prescription use only under the direction of a healthcare professional. However, it's important to note that Zephyr Sleep Technologies, the company behind MATRx plus, ceased operations in June 2021, meaning the device is no longer available for sale or support.
Yes, MATRx plus was not recommended for patients with loose teeth, advanced periodontal disease, full dentures, or dental implants. It was also not to be used as an apnea monitor or in life-supporting situations, and its use did not replace the need for follow-up testing to determine ongoing therapy effectiveness.
Alternatives for OSA assessment and treatment include traditional in-lab polysomnography or other home sleep tests for diagnosis, and for treatment, options like CPAP, BiPAP, EPAP devices, other oral appliances, myofunctional therapy, positional therapy, and surgical interventions. The MATRx plus specifically focused on identifying suitability for oral appliance therapy.
Specific pricing models for MATRx plus are no longer relevant as Zephyr Sleep Technologies ceased operations in June 2021, and the device is not available for purchase. Generally, the cost of oral appliances for OSA can vary significantly, ranging from minimal out-of-pocket expenses to several thousand dollars depending on insurance coverage.
MATRx plus featured a tablet-based design with instructional videos for patients to self-administer the test at home. It offered real-time cloud connectivity, allowing patient study data to be simultaneously accessible to the dentist's office, sleep physician's office, and Zephyr's servers for collaboration.
Physicians retain ultimate responsibility for patient care, even when utilizing AI tools, and must understand how such tools work, including their appropriate use cases and limitations. While MATRx plus provided data to aid in decision-making, it did not replace the need for clinical judgment, titration, or follow-up testing.

Related Tools

Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
MeRT System
Wave Neuroscience
Mental & Behavioral Health AI
MeRT (Magnetic e-Resonance Therapy) is an advanced, personalized form of TMS that uses your own brainwave data to guide treatment. It's a non-invasive, drug-free option designed to help the brain communicate more efficiently so symptoms of conditions like depression, anxiety, PTSD, TBI, autism, and more can improve.
Brainomix 360 Hyperdensity
Brainomix Limited
Neurology AI
Brainomix 360 Hyperdensity is an AI-powered neuroimaging software tool that detects and quantifies brain hyperdensities on CT scans, forming a crucial part of the Brainomix 360 Stroke platform for rapid and accurate stroke assessment.
SOMNUM
HoneyNaps
Clinical Decision Support & Reference
SOMNUM is an AI-enabled medical software tool by Honeynaps Co., Ltd. that provides comprehensive sleep analysis to aid in the diagnosis and management of sleep disorders.
DETECT-ME/CFS project
DETECT-ME/CFS project (ME/CFS Research Foundation)
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.